Press Enter to search · ESC to close

Macro

Pfizer’s Hemophilia Drug Approved in China for New Indication

Pfizer said China’s National Medical Products Administration approved a new indication for its hemophilia therapy Beqvez (fidanacogene elaparvovec), a once-weekly fixed-dose subcutaneous non-factor treatment. The approval covers routine prophylaxis for patients aged 12 and older weighing at least 35 kg with hemophilia A with factor VIII inhibitors or hemophilia B with factor IX inhibitors, to prevent bleeding or reduce bleeding frequency.

Share

Related News

Cointime share card
Long-press the image to save or share
Pitch us Community Feedback